吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

交易中 08-20 09:56:15 EDT

145.42

-2.18

-1.48%

最高146.71	最低144.78	成交量37.59万
今开146.26	昨收147.60	日振幅1.30%
总市值1,804亿	流通市值1,800亿	总股本12.41亿
成交额5,479万	换手率0.03%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":145.415,"timestamp":1787234175332,"preClose":147.6,"halted":0,"volume":375853,"delay":0,"changeRate":-0.014803523035230368,"floatShares":1238162880,"shares":1240679623,"eps":-2.614993,"marketStatus":"交易中","change":-2.185,"latestTime":"08-20 09:56:15 EDT","open":146.26,"high":146.705,"low":144.784,"amount":54791177.56313,"amplitude":0.013015,"askPrice":145.4,"askSize":20,"bidPrice":145.35,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.614993,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787256000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":147.6,"dividendRate":0.022128,"preHourTrading":{"tag":"盘前","latestPrice":146.2,"preClose":147.6,"latestTime":"09:28 EDT","volume":3654,"amount":535394.96892,"timestamp":1787232499373,"change":-1.4,"changeRate":-0.009485,"amplitude":0.021409},"postHourTrading":{"tag":"盘后","latestPrice":147.01,"preClose":147.6,"latestTime":"19:59 EDT","volume":432661,"amount":63857352.8001,"timestamp":1787183945359,"change":-0.59,"changeRate":-0.003997,"amplitude":0.015138},"volumeRatio":1.09708,"impliedVol":0.2848,"impliedVolPercentile":0.259},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"1112102407","title":"异动解读｜吉利德科学盘中上涨3.15%，78亿美元收购Arcellx持续提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1112102407","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112102407?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:51","pubTimestamp":1787147470,"startTime":"0","endTime":"0","summary":"8月19日，吉利德科学盘中上涨3.15%，报147.675美元/股，成交额1.01亿美元。消息面上，吉利德科学于8月18日宣布将以78亿美元股权价值收购癌症疗法研发公司Arcellx，每股支付115美元现金外加每股5美元或有价值权，较Arcellx上一交易日收盘价溢价87%，市场将此视为公司进一步强化肿瘤学管线的重大战略举措。此外，公司Q2营收78亿美元超市场预期，全年亏损指引收窄至每股0.30至0.65美元，优于分析师预估的每股亏损0.75美元，基本面改善叠加并购利好持续推升股价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158603682","title":"异动解读｜吉利德科学盘中上涨3.05%，宣布78亿美元收购Arcellx加码肿瘤管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1158603682","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158603682?lang=zh_cn&edition=full","pubTime":"2026-08-18 23:33","pubTimestamp":1787067194,"startTime":"0","endTime":"0","summary":"8月18日，吉利德科学盘中上涨3.05%，报143.155美元/股，成交额2.35亿美元。消息面上，吉利德科学周一宣布将以78亿美元股权价值收购癌症疗法研发公司Arcellx，每股支付115美元现金外加每股5美元或有价值权，较Arcellx上一交易日收盘价溢价87%。此举被视为吉利德进一步强化肿瘤学管线的战略举措。同时，公司最新季度财报显示营收78亿美元超预期，全年亏损指引亦收窄至每股0.30至0.65美元，优于市场预估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137034601","title":"异动解读｜吉利德科学盘中下跌3.03%，Q2因收购研发费用转亏引发市场抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1137034601","media":"行情直击","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137034601?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:49","pubTimestamp":1785941362,"startTime":"0","endTime":"0","summary":"8月5日，吉利德科学盘中下跌3.03%，报131.15美元/股，成交额5.23亿美元。消息面上，公司于8月4日盘后公布第二季度业绩，营收78亿美元同比增长10%，调整后每股亏损6.75美元，均优于市场预期。然而，近期收购产生的每股9.08美元知识产权研发及税务费用使公司由盈转亏。此外，新冠药物Veklury销售额暴跌81%至2300万美元，全年预测从约6亿美元腰斩至约3亿美元。高管还透露，ACA税收补贴取消导致部分患者失去医保覆盖，Q2艾滋病治疗市场趋软。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"吉利德科学盘中下跌3.03%，Q2因收购研发费用转亏引发市场抛压","news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108157113","title":"吉利德科学高管：Q2艾滋病治疗市场趋软，ACA税收补贴取消致部分民众失去医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1108157113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108157113?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:32","pubTimestamp":1785879128,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管在财报电话会议中透露，第二季度艾滋病治疗市场呈现疲软态势。究其原因，部分患者因《平价医疗法案》（ACA）税收补贴取消而失去保险计划，导致市场购买力下降，对整个行业形成冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","IE00BSNM7G36.USD","LU0234570918.USD","BIB","LU0882574055.USD","LU1430594728.SGD","LU1037948897.HKD","LU1674673428.USD","LU0289739699.SGD","SG9999015978.USD","BK4585","LU1066053197.SGD","LU0965509283.SGD","BK4578","LU0965509010.AUD","LU1023059063.AUD","LU1934455277.USD","LU0114720955.EUR","LU0889565916.HKD","IE00B19Z3B42.SGD","BBH","LU0058720904.USD","LU2324357040.USD","LU2112291526.USD","MEDI","LU2468319806.SGD","IE00BZ1G4Q59.USD","IE0002270589.USD","LU0965509101.SGD","LU1934455863.HKD","IE00B7SZLL34.SGD","LU0109394709.USD","LU1674673691.USD","SG9999015952.SGD","LU2087621335.USD","BK4566","LU0823416689.USD","LU1066051498.USD","LU1778281490.HKD","LU1839511570.USD","LU1934455194.USD","BK4532","BK4550","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU1057294990.SGD","BMED","LU0861579265.USD","LU1585245621.USD","SG9999015945.SGD","LU0122379950.USD","LU1571399168.USD","GILD","SG9999015986.USD","BK4588","IBBQ","LU2089984988.USD","BK4568","LU0320765992.SGD","LU1037948541.HKD","BK4139","TBXU","BK4583","TMED","LU0965508806.USD","IE00B3T34201.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100032335","title":"吉利德科学高管：今年暂无计划进行大规模并购交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1100032335","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100032335?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:12","pubTimestamp":1785877926,"startTime":"0","endTime":"0","summary":"吉利德科学公司高管在电话会议上表示，目前不预计今年会进行额外的大规模并购交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455194.USD","BK4588","BK4550","IE00BZ1G4Q59.USD","LU0114720955.EUR","SG9999015986.USD","TBXU","BBH","LU2324357040.USD","BMED","BK4568","LU0823416689.USD","LU1023059063.AUD","LU1037948541.HKD","IBB","LU1674673691.USD","IE00B3T34201.USD","LU1066051498.USD","LU1057294990.SGD","SG9999015952.SGD","LU2468319806.SGD","GILD","LU0882574055.USD","LU0058720904.USD","TMED","IBBQ","LU0889565916.HKD","SG9999015978.USD","IE0002270589.USD","LU0965508806.USD","MEDI","LU1430594728.SGD","LU1674673428.USD","LU0234570918.USD","LU0861579265.USD","LU0289739699.SGD","BK4566","LU0965509283.SGD","LU1571399168.USD","IE00B7SZLL34.SGD","LU0965509101.SGD","LU1778281490.HKD","LU1934455863.HKD","LU1066053197.SGD","SG9999015945.SGD","IE00BSNM7G36.USD","LU1839511570.USD","BK4139","BK4583","LU2087621335.USD","LU0122379950.USD","LU1934455277.USD","LU1037948897.HKD","IE00B19Z3581.USD","LU0965509010.AUD","LU2089984988.USD","IE00BKVL7J92.USD","LU2112291526.USD","BK4578","LU1585245621.USD","LU0109394709.USD","IE00B19Z3B42.SGD","BIB","LU0320765992.SGD","LU1061106388.HKD","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657679605","title":"吉利德科学于2026年8月4日公布了2026年第二季度财务业绩。总收入同比增长10%达到78亿美元主要得益于不包括Vek","url":"https://stock-news.laohu8.com/highlight/detail?id=2657679605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657679605?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:10","pubTimestamp":1785877839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015978.USD","LU2087621335.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","LU2468319806.SGD","IE00BKVL7J92.USD","LU1778281490.HKD","LU1839511570.USD","LU0882574055.USD","LU0965508806.USD","BK4583","IBB","LU0965509010.AUD","TBXU","LU0823416689.USD","LU1430594728.SGD","LU2324357040.USD","MEDI","LU0234570918.USD","SG9999015986.USD","LU1571399168.USD","LU1674673428.USD","SG9999015952.SGD","GILD","BK4568","BMED","LU1023059063.AUD","LU0122379950.USD","BK4550","LU0058720904.USD","LU0861579265.USD","LU2089984988.USD","BIB","IE00B7SZLL34.SGD","LU1061106388.HKD","LU0109394709.USD","IE00BSNM7G36.USD","IBBQ","LU0965509283.SGD","LU0114720955.EUR","LU1066051498.USD","TMED","IE00B19Z3581.USD","IE0002270589.USD","BK4585","LU0889565916.HKD","LU1037948541.HKD","LU1934455277.USD","IE00BZ1G4Q59.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567644","title":"吉利德科学公司因研发成本转亏，HIV药物销售提振营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567644","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657567644?lang=zh_cn&edition=full","pubTime":"2026-08-05 05:09","pubTimestamp":1785877740,"startTime":"0","endTime":"0","summary":"吉利德科学公司于美股周二收盘后公布业绩，第二季度营收增长，主要得益于HIV产品销售额的提升，但近期收购产生的新研发支出使公司整体转盈为亏。剔除某些一次性项目后，吉利德报告调整后每股亏损6.75美元。吉利德表示，本季度新冠治疗药物Veklury销售额下降81%，至2300万美元，主要因新冠住院率降低。公司将Veklury全年销售预测下调至约3亿美元，此前预期约为6亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimezkr3752456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135051692","title":"吉利德高管在电话会议中宣布：全年HIV业务增长预期上调至9%-10%，此前指引为8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135051692","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135051692?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:42","pubTimestamp":1785876147,"startTime":"0","endTime":"0","summary":"吉利德（Gilead Sciences）高管在电话会议上透露，公司已将全年HIV业务增长预期上调至9%至10%的区间。这一调整较此前8%的增长指引显著提升，展现了公司对该业务领域强劲势头的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B3T34201.USD","IBBQ","LU0058720904.USD","LU0823416689.USD","LU0965509010.AUD","BK4532","LU0965509283.SGD","LU1585245621.USD","LU1934455194.USD","LU1674673428.USD","LU1061106388.HKD","LU2087621335.USD","LU1057294990.SGD","BK4550","BK4588","LU0109394709.USD","BK4578","LU1934455277.USD","MEDI","BBH","IBB","LU1066051498.USD","LU0882574055.USD","LU1037948541.HKD","GILD","IE00BSNM7G36.USD","BK4583","BK4566","BK4585","BIB","LU1674673691.USD","LU2468319806.SGD","LU0289739699.SGD","LU1934455863.HKD","SG9999015986.USD","TMED","IE00BKVL7J92.USD","LU0965508806.USD","BK4139","LU1430594728.SGD","LU1571399168.USD","SG9999015945.SGD","LU0889565916.HKD","SG9999015978.USD","LU2112291526.USD","BK4568","LU0234570918.USD","IE00B19Z3581.USD","LU0861579265.USD","LU0965509101.SGD","LU0122379950.USD","LU2324357040.USD","LU1778281490.HKD","LU1023059063.AUD","BMED","LU1037948897.HKD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1839511570.USD","LU0320765992.SGD","TBXU","LU1066053197.SGD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145483121","title":"吉利德高管：距FDA PDUFA日期仅剩五个月，Anito-Cel细胞疗法上市筹备工作已全面启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1145483121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145483121?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:42","pubTimestamp":1785876146,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管透露，针对其重磅细胞疗法Anito-Cel的上市准备工作已全面铺开，目前距离美国食品药品监督管理局（FDA）设定的PDUFA目标日期仅剩五个月时间。这一消息源自公司近期召开的电话会议。\n在会议中，高管进一步强调，公司正紧锣密鼓地推进各项筹备事项，以确保一旦获批，该疗法能够迅速进入市场。Anito-Cel作为一种前沿的细胞治疗产品，被视为吉利德在肿瘤学领域布局的关键一环。随着最终审批日期的临近，市场对这款疗法的商业化前景给予高度关注，而吉利德方面则展现出对既定时间表与执行能力的充分信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU1571399168.USD","LU1674673691.USD","LU0965509010.AUD","LU1934455194.USD","LU2087621335.USD","MEDI","LU0965509101.SGD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU1585245621.USD","LU2112291526.USD","BK4532","LU0861579265.USD","BK4588","LU1066053197.SGD","LU1430594728.SGD","LU1037948541.HKD","LU0122379950.USD","LU2089984988.USD","LU1934455277.USD","BK4550","BBH","LU0823416689.USD","LU0965509283.SGD","LU0109394709.USD","TMED","SG9999015952.SGD","SG9999015986.USD","LU1057294990.SGD","IE00B19Z3581.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU0889565916.HKD","BMED","BK4578","LU2468319806.SGD","SG9999015945.SGD","LU1934455863.HKD","LU2324357040.USD","LU1037948897.HKD","LU1023059063.AUD","SG9999015978.USD","LU1674673428.USD","BK4139","BIB","LU0114720955.EUR","TBXU","GILD","IE00B7SZLL34.SGD","LU0882574055.USD","BK4568","LU1061106388.HKD","LU1839511570.USD","LU0965508806.USD","LU0289739699.SGD","BK4566","BK4583","BK4585","IBB","IE00B3T34201.USD","LU0234570918.USD","LU1066051498.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163992816","title":"吉利德科学第二季度调整后每股收益-6.75美元，高于IBES预估-7.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163992816","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163992816?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:17","pubTimestamp":1785874678,"startTime":"0","endTime":"0","summary":"8月4日，吉利德科学（Gilead Sciences）公布第二季度产品销售额达76.27亿美元。第二季度调整后每股收益为-6.75美元，优于IBES预估的-7.24美元。","market":"us","thumbnail":"https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2324357040.USD","SG9999015952.SGD","LU1674673691.USD","LU1674673428.USD","LU1023059063.AUD","SG9999015986.USD","LU0058720904.USD","SG9999015945.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0122379950.USD","LU2087621335.USD","LU1585245621.USD","IBBQ","LU0861579265.USD","LU0882574055.USD","LU1778281490.HKD","LU0965509283.SGD","LU2468319806.SGD","LU1934455194.USD","MEDI","IE00BSNM7G36.USD","LU1430594728.SGD","BK4585","BK4550","BK4583","BK4588","LU1934455863.HKD","LU0289739699.SGD","LU1057294990.SGD","LU1066051498.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU1037948897.HKD","BK4578","LU0823416689.USD","SG9999015978.USD","BMED","IE00B7SZLL34.SGD","BK4568","LU2089984988.USD","LU0114720955.EUR","BK4532","TBXU","LU1061106388.HKD","BBH","LU0965508806.USD","LU1934455277.USD","BK4139","LU1066053197.SGD","IBB","LU0965509010.AUD","GILD","IE00B19Z3B42.SGD","LU0965509101.SGD","TMED","LU0234570918.USD","LU1839511570.USD","LU1037948541.HKD","LU2112291526.USD","BIB","LU0109394709.USD","IE00B3T34201.USD","LU1571399168.USD","IE0002270589.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108344321","title":"吉利德科学：季度调整后每股亏损6.75美元，反映近期收购带来的每股9.08美元知识产权研发及税务支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1108344321","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108344321?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:04","pubTimestamp":1785873878,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）最新季度业绩揭晓。数据显示，公司调整后每股收益为-6.75美元。这一数字背后，折射出近期收购活动所产生的重大财务影响——具体而言，每股9.08美元的知识产权研发成本与税务费用被计入。这些支出，均与公司近期完成的收购交易紧密相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0058720904.USD","BK4585","LU1585245621.USD","LU2089984988.USD","SG9999015978.USD","MEDI","IE0002270589.USD","BBH","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0965509283.SGD","IE00B7SZLL34.SGD","LU1571399168.USD","BK4550","BIB","LU2087621335.USD","LU0109394709.USD","LU0965509101.SGD","LU2468319806.SGD","LU1066051498.USD","SG9999015952.SGD","LU0234570918.USD","BK4532","LU0122379950.USD","LU0823416689.USD","BK4139","LU0861579265.USD","LU1023059063.AUD","LU1674673691.USD","LU1934455194.USD","SG9999015945.SGD","IBBQ","BK4583","LU1066053197.SGD","BMED","LU0289739699.SGD","IE00B19Z3581.USD","BK4566","SG9999015986.USD","IE00BSNM7G36.USD","LU2324357040.USD","TMED","LU0965508806.USD","LU0882574055.USD","GILD","IE00B3T34201.USD","LU1934455277.USD","LU0965509010.AUD","LU1057294990.SGD","IBB","BK4578","LU1839511570.USD","LU1674673428.USD","LU0114720955.EUR","LU1061106388.HKD","LU1430594728.SGD","LU1037948541.HKD","LU2112291526.USD","LU1037948897.HKD","LU1778281490.HKD","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","TBXU","LU0889565916.HKD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187256046","title":"加州最高法院裁定吉利德科学胜诉，HIV药物“创新责任”案尘埃落定","url":"https://stock-news.laohu8.com/highlight/detail?id=1187256046","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187256046?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:01","pubTimestamp":1785776475,"startTime":"0","endTime":"0","summary":"加州最高法院近期作出裁决，判定吉利德科学在一起涉及HIV药物的“创新责任”案件中胜诉。原告方曾指控吉利德，声称其明知旧款HIV药物存在肾毒性风险，却故意拖延新一代、更安全药物的研发与上市，造成了患者不必要的伤害。对于吉利德而言，这无疑是一场关键胜利，避免了潜在的巨额赔偿和声誉受损。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","LU1066051498.USD","LU1778281490.HKD","LU2468319806.SGD","SG9999015945.SGD","LU0965509283.SGD","LU2089984988.USD","TMED","LU1066053197.SGD","LU0320765992.SGD","BK4588","IBB","IE00B19Z3B42.SGD","LU1037948541.HKD","TBXU","IE00B7SZLL34.SGD","LU1839511570.USD","LU0882574055.USD","BK4532","LU0965508806.USD","LU1430594728.SGD","LU0114720955.EUR","LU1674673691.USD","LU1934455863.HKD","LU0058720904.USD","IBBQ","BK4578","IE00BZ1G4Q59.USD","LU0109394709.USD","BK4568","LU1037948897.HKD","SG9999015986.USD","IE00BKVL7J92.USD","LU0861579265.USD","IE0002270589.USD","LU0823416689.USD","IE00B3T34201.USD","LU0889565916.HKD","LU1061106388.HKD","GILD","LU1571399168.USD","LU1674673428.USD","BK4550","IE00BSNM7G36.USD","LU0965509010.AUD","LU2324357040.USD","LU2087621335.USD","BMED","LU0289739699.SGD","BIB","LU1023059063.AUD","LU2112291526.USD","SG9999015978.USD","LU0234570918.USD","BK4139","LU1057294990.SGD","LU1585245621.USD","LU0965509101.SGD","MEDI","SG9999015952.SGD","IE00B19Z3581.USD","BBH","LU1934455194.USD","LU0122379950.USD","BK4585","BK4566","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179747532","title":"异动解读｜吉利德科学盘中下跌3.02%，生物科技板块普跌拖累短线回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1179747532","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179747532?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:59","pubTimestamp":1785423548,"startTime":"0","endTime":"0","summary":"7月30日，吉利德科学盘中下跌3.02%，报129.24美元/股，成交额1.94亿美元。消息面上，当日生物科技板块整体承压，阿尔尼拉姆制药大跌26.38%、Madrigal Pharmaceuticals跌12.57%、艾伯维跌2.82%、安进跌1.86%，板块联动效应明显。此前两个交易日吉利德科学受财报预期升温及Trodelvy管线利好驱动连续上涨逾6%，短线获利了结压力叠加板块整体回调，股价出现技术性调整。此外，巴克莱近日将其目标价由155美元下调至145美元，维持同等权重评级，亦在一定程度上压制市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132525105","title":"异动解读｜吉利德科学夜盘上涨3.46%，财报预期升温叠加肿瘤管线利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1132525105","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132525105?lang=zh_cn&edition=full","pubTime":"2026-07-29 12:11","pubTimestamp":1785298282,"startTime":"0","endTime":"0","summary":"7月29日，吉利德科学夜盘上涨3.46%，报138.97美元/股，成交额1.19万美元。消息面上，公司将于8月4日盘后发布二季度财报，市场预计营收同比增长6.13%，机构整体观点偏多，FactSet统计均值目标价159.04美元。近期催化剂密集落地：7月24日欧洲药品管理局CHMP推荐Trodelvy联合Keytruda用于PD-L1阳性一线转移性三阴性乳腺癌，叠加此前FDA已批准Trodelvy一线适应症，产品放量预期持续强化。此外，HIV管线方面每周一次口服lenacapavir获FDA补充新药申请受理，管线推进节奏良好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"吉利德科学夜盘上涨3.46%，财报预期升温叠加肿瘤管线利好持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107460667","title":"异动解读｜吉利德科学盘中上涨3.13%，生物科技板块普涨叠加财报预期升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1107460667","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107460667?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:26","pubTimestamp":1785248777,"startTime":"0","endTime":"0","summary":"7月28日，吉利德科学盘中上涨3.13%，报135.76美元/股，成交额2.47亿美元。当日生物科技板块整体走强，安进涨5.67%、因塞特医疗涨4.67%、艾伯维涨3.66%，板块联动效应明显。消息面上，公司将于8月4日盘后发布季度财报，市场预计营收同比增长6.13%，机构观点偏多。此前该药已获FDA批准一线适应症，产品放量预期持续强化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027040","title":"Bitget 已上线 SKDD、GILD、TMF 等 9 只股票永续合约","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027040","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654027040?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:11","pubTimestamp":1785208272,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方公告，为满足用户多元化投资需求，Bitget 已上线 SKDD（2 倍做空 SK 海力士 ETF）、SKUU（2 倍做多 SK 海力士 ETF）、GILD（Gilead Sciences）、TMF（3 倍做多美国长期国债 ETF）等 9 只股票及 ETF 永续合约。\n\n上述合约均以 USDT 结算，支持最高 20 倍杠杆和 7×24 小时交易。更多详情可参阅 Bitget 官方平台。\n\n\n ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2278557","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU0823416689.USD","LU0289739699.SGD","LU1934455194.USD","BIB","BBH","LU2324357040.USD","BK4550","SG9999015945.SGD","TBXU","BK4578","LU0320765992.SGD","LU0882574055.USD","LU0965509283.SGD","MEDI","IE00B7SZLL34.SGD","BK4139","LU1066053197.SGD","BK4583","BK4532","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU0965508806.USD","LU1839511570.USD","IBB","LU1674673428.USD","BK4588","BK4566","LU0965509101.SGD","LU0114720955.EUR","LU0861579265.USD","LU1934455863.HKD","SG9999015986.USD","LU2112291526.USD","IE0002270589.USD","LU1674673691.USD","SG9999015978.USD","LU0058720904.USD","TMED","LU1037948541.HKD","GILD","BMED","IE00BKVL7J92.USD","LU1061106388.HKD","LU1934455277.USD","SG9999015952.SGD","LU0109394709.USD","LU0122379950.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192595101","title":"财报前瞻｜吉利德科学本季度营收预计增6.13%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1192595101","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192595101?lang=zh_cn&edition=full","pubTime":"2026-07-28 08:20","pubTimestamp":1785198049,"startTime":"0","endTime":"0","summary":"吉利德科学将于2026年08月04日盘后发布新一季财报，市场关注一次性研发并购费用对利润的冲击与HIV/肿瘤新产品放量进展。公司当前主营由“产品”构成的核心业务贡献度高，上季度产品收入69.46亿美元，占比99.80%，收入结构稳定。营收与每股收益均小幅超出市场预期，息税前利润同比增12.93%，经营韧性延续。本季度看点集中在HIV产品线的代际升级与可及性提升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜吉利德科学本季度营收预计增6.13%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653895100","title":"吉利德科学(GILD)肿瘤组合疗法获欧洲药品管理局旗下CHMP推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653895100","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653895100?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:45","pubTimestamp":1784889935,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学 宣布，欧洲药品管理局旗下人用药品委员会已发布积极意见，建议批准其Trop-2靶向ADC药物Trodelvy联合帕博利珠单抗，用于既往未接受过全身治疗、且肿瘤PD-L1表达阳性的不可切除局部晚期或转移性三阴性乳腺癌成人患者。若欧盟委员会于2026年晚些时候正式批准该联合疗法，Trodelvy将实现从单药到联合疗法、全面覆盖不同PD-L1表达状态的mTNBC一线治疗布局。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302998","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","GILD","LU0320765992.SGD","IE00BSNM7G36.USD","LU1037948541.HKD","SG9999015945.SGD","LU0289739699.SGD","IBBQ","LU1066051498.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","LU1585245621.USD","LU0234570918.USD","LU1571399168.USD","BK4550","LU0122379950.USD","TBXU","LU1061106388.HKD","IE0002270589.USD","BK4578","LU0889565916.HKD","TMED","SG9999015978.USD","IE00B19Z3581.USD","BK4585","MEDI","LU2089984988.USD","CHMP","BK4139","LU1057294990.SGD","BIB","SG9999015952.SGD","LU2324357040.USD","IE00B3T34201.USD","LU1934455863.HKD","BK4583","LU2087621335.USD","BBH","LU0965508806.USD","BK4588","IBB","LU0058720904.USD","LU0823416689.USD","LU1023059063.AUD","SG9999015986.USD","BK4568","LU1934455194.USD","LU0965509101.SGD","BMED","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185859812","title":"CHMP推荐吉利德Trodelvy®联合Keytruda®用于PD-(L)1阳性一线转移性三阴性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1185859812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185859812?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:29","pubTimestamp":1784888958,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用药品委员会（CHMP）近日给出推荐意见，支持吉利德科学的Trodelvy®与Keytruda®联合使用，用于治疗PD-(L)1阳性的一线转移性三阴性乳腺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU0861579265.USD","LU0965508806.USD","LU1057294990.SGD","LU1066051498.USD","LU1778281490.HKD","LU0965509283.SGD","SG9999015952.SGD","BK4550","BK4585","LU1571399168.USD","LU2112291526.USD","LU1037948897.HKD","LU0109394709.USD","LU1839511570.USD","TMED","IE00B3T34201.USD","BMED","BIB","LU1585245621.USD","BK4568","GILD","IE00B7SZLL34.SGD","IBBQ","LU0289739699.SGD","LU1037948541.HKD","BK4566","LU1674673691.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","TBXU","BBH","LU0234570918.USD","LU2089984988.USD","LU2087621335.USD","LU1061106388.HKD","LU1430594728.SGD","IE00BKVL7J92.USD","LU1066053197.SGD","LU0823416689.USD","LU1934455194.USD","BK4583","LU0965509010.AUD","IE0002270589.USD","LU0058720904.USD","BK4588","LU0882574055.USD","IE00B19Z3581.USD","SG9999015945.SGD","LU0889565916.HKD","LU2324357040.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","LU1934455277.USD","LU1023059063.AUD","LU1934455863.HKD","BK4139","IE00BSNM7G36.USD","LU0122379950.USD","SG9999015986.USD","LU0114720955.EUR","SG9999015978.USD","BK4532","LU2468319806.SGD","BK4578","LU0965509101.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169878111","title":"Leerink Partners下调吉利德科学评级至“与大盘持平”，目标价大幅调降至127美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169878111","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169878111?lang=zh_cn&edition=full","pubTime":"2026-07-21 12:03","pubTimestamp":1784606620,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners调整了对生物技术公司吉利德科学的股票评级。该机构将其评级从原先的“跑赢大盘”下调至“与大盘持平”，反映出其对该公司近期前景更为审慎的看法。\n与此同时，Leerink Partners也显著下调了吉利德科学的目标股价，从每股146美元大幅削减至127美元。这一调整意味着该机构对该公司未来股价的预期有所降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","GILD","LU1934455194.USD","LU1066051498.USD","BK4139","LU0861579265.USD","LU2087621335.USD","LU2112291526.USD","LU0965509010.AUD","LU2324357040.USD","TBXU","BK4585","IE00B7SZLL34.SGD","LU1839511570.USD","LU1674673691.USD","LU0889565916.HKD","BBH","IBBQ","SG9999015952.SGD","IE00B3T34201.USD","LU1057294990.SGD","LU1430594728.SGD","BK4583","IE00B19Z3B42.SGD","BIB","SG9999015986.USD","MEDI","IE00B19Z3581.USD","BK4568","LU1037948541.HKD","IE00BKVL7J92.USD","LU1037948897.HKD","LU0114720955.EUR","LU0823416689.USD","LU0965509101.SGD","BMED","LU0965509283.SGD","LU1934455863.HKD","BK4566","IE0002270589.USD","LU0965508806.USD","IE00BSNM7G36.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","SG9999015978.USD","BK4578","LU1571399168.USD","LU1778281490.HKD","LU1934455277.USD","BK4550","LU0122379950.USD","BK4532","BK4588","LU1066053197.SGD","LU0882574055.USD","LU2468319806.SGD","LU0234570918.USD","LU1674673428.USD","LU2089984988.USD","IBB","LU0109394709.USD","LU0289739699.SGD","LU1023059063.AUD","LU0058720904.USD","LU1061106388.HKD","TMED","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":0.0863},{"period":"1month","weight":0.108},{"period":"3month","weight":0.131},{"period":"6month","weight":-0.0251},{"period":"1year","weight":0.2511},{"period":"ytd","weight":0.2025}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.009883},{"month":5,"riseRate":0.571429,"avgChangeRate":0.020601},{"month":6,"riseRate":0.628571,"avgChangeRate":0.02322},{"month":7,"riseRate":0.571429,"avgChangeRate":0.016506},{"month":8,"riseRate":0.571429,"avgChangeRate":0.036027},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}